Muscle Damage
Tired of all the misinformation spread by supplement companies?
Learn what works, what's a waste, and how to achieve your health goals with our free supplement mini-course.
Need guidance?
If you need something quick and easy to let you see which supplements do what to your health (and vice versa), check out our A-to-Z Supplement Reference.
If you are looking for clear directions that will save you time and money and help improve your health, then you need our Supplement Guides.
Human Effect Matrix
The Human Effect Matrix looks at human studies (it excludes animal and in vitro studies) to tell you what supplements affect muscle damage
| Grade | Level of Evidence [show legend] |
|---|---|
|
Robust research conducted with repeated double-blind clinical trials |
|
Multiple studies where at least two are double-blind and placebo controlled |
|
Single double-blind study or multiple cohort studies |
|
Uncontrolled or observational studies only |
|
Level of Evidence
?
The amount of high quality evidence. The more
evidence, the more we can trust the results.
|
Outcome |
Magnitude of effect
?
The direction and size of the supplement's impact on
each outcome. Some supplements can have an increasing effect, others have a decreasing effect, and others have no effect.
|
Consistency of research results
?
Scientific research does not always agree. HIGH or
VERY HIGH means that most of the scientific research agrees.
|
Notes |
|---|---|---|---|---|
|
|
Notable
|
High See all 3 studies |
Decrease creatine kinase exists following acute supplementation (15-30 minutes before a workout) of HMB free acid to about a third of control, and is effective in trained individuals
|
|
|
|
Minor
|
Moderate See all 6 studies |
Not overly protective, but there appears to be a degree of protection.
|
|
|
|
Minor
|
Very High See all 4 studies |
Biomarkers of muscle damage including creatine kinase and muscle soreness are both fairly reliably reduced following ingestion of carnitine and pairing with exercise
|
|
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||